SWOG clinical trial number
S2506
MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Open
Phase
Accrual
0%
Abbreviated Title
Testing mosunetuzumab alone, with zanubrutinib, and with polatuzumab vedotin for treating marginal zone lymphoma that came back or didn’t get better with treatment
Status Notes
Effective 08/18/2026, S2506 is open to accrual.
Activated
08/18/2026
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS
Research committees
Lymphoma
Treatment
Mosunetuzumab
Polatuzumab vedotin
Zanubrutinib
Other Clinical Trials
SWOG Clinical Trial Number
S2506
MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
69%
Open
Phase